Future Appears Grim For Pfizer's Tanezumab With Ostearthritis Trial Stopped
This article was originally published in The Pink Sheet Daily
Executive Summary
Because tanezumab is the anti-NGF farthest along in development, adverse event reports could spell trouble for the entire planned class of analgesics.